Patient-perceived benefits and risks of off-label use of SGLT2 inhibitors and GLP-1 receptor agonists in type 1 diabetes: a structured qualitative assessment

BACKGROUND: Patients with type 1 diabetes mellitus (T1DM) may have suboptimal glucose control and are interested in the use of adjuvant therapies. OBJECTIVES: To determine, from the patients’ perspective, the reasons for initiation of glucagon-like peptide 1 receptor agonist (GLP-1RA) and/or sodium...

Descripción completa

Detalles Bibliográficos
Autores principales: Edwards, Khary, Uruska, Aleksandra, Duda-Sobczak, Anna, Zozulinska-Ziolkiewicz, Dorota, Lingvay, Ildiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10334016/
https://www.ncbi.nlm.nih.gov/pubmed/37440840
http://dx.doi.org/10.1177/20420188231180987

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10334016/
https://www.ncbi.nlm.nih.gov/pubmed/37440840
http://dx.doi.org/10.1177/20420188231180987

Ejemplares similares